Pitavastatin: efficacy and safety in intensive lipid lowering
Authors:
- Toshio HayashiTHToshio Hayashi
- Koutaro YokoteKYKoutaro Yokote
- Yasushi SaitoYSYasushi Saito
- Akihisa IguchiAIAkihisa Iguchi
- 10 October 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 8 (14) , 2315-2327
Abstract
Pitavastatin, (+)-monocalcium bis(3R,5S,6E)-7-(2-cyclopropyl-4-[4-fluorophenyl]-3-quinolyl-3,5-dihydroxy-6-heptenoate), is a totally synthetic statin developed in Japan with a molecular weight of 880.98. Pitavastatin achieves its potent pharmacologic action by strongly binding and inhibiting the active site of 3-hydroxy-3-methyl-glutaryl-CoA reductase, and has potent low-density lipoprotein-cholesterol-lowering effects similar to atorvastatin and rosuvastatin. One other characteristic of the agent is that pitavastatin is minimally metabolized by the cytochrome P450 isozymes; it undergoes glucuronidation and is converted to the inactive lactone form, and, therefore, the incidence of any drug interactions is reduced. Due to the promising results observed in clinical trials, it has the potential to be an excellent addition to the worldwide lipid management market.Keywords
This publication has 46 references indexed in Scilit:
- Statin guidelines should give best statinBMJ, 2006
- Enhanced oxidative stress in neutrophils from hyperlipidemic guinea pigAtherosclerosis, 2005
- Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cellsLife Sciences, 2005
- PitavastatinInternational Journal Of Clinical Practice, 2005
- A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbitsAtherosclerosis, 2004
- MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathwayLife Sciences, 2004
- Pitavastatin-Induced Thrombomodulin Expression by Endothelial Cells Acts Via Inhibition of Small G Proteins of the Rho FamilyArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic DyslipidemiaDiabetes Care, 2001
- NK-104: a novel synthetic HMG-CoA reductase inhibitorExpert Opinion on Investigational Drugs, 2000
- Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemiaThe American Journal of Cardiology, 2000